Introduction: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection.

Methods: This is a multicenter, randomized, open-label study. Adult patients with confirmed SARS-CoV-2 infection with initial cycle threshold (Ct) value < 30 and symptom onset within 4 days were enrolled. Eligible patients were randomized in a 2:1 ratio to receive a single 250-µg dose of ropeginterferon alfa-2b subcutaneously plus standard of care (SOC) or to receive SOC alone. The primary endpoint was the proportion of patients with a negative RT-PCR result for SARS-CoV-2 or discharged from the hospital before Day 8. Change in clinical status based on the World Health Organization (WHO) clinical progression scale and pulmonary infiltrations through chest radiograph were also evaluated.

Results: A total of 132 patients were enrolled and treated with study medication. Higher percentages of patients who achieved Ct ≥ 30 or were discharged from the hospital were observed on Day 8 and every other time point of assessment, i.e., Days 5, 11, 15, and 22, in the ropeginterferon alfa-2b group compared to the SOC alone group. However, the difference was statistically significant on Day 11 but not on Day 8. The primary endpoint was not met. The ropeginterferon alfa-2b group showed a higher improvement rate in lung infiltration on Day 5 (27.6% vs. 0.0%, p = 0.0087) and a higher improvement rate in WHO clinical progression scores on Day 8 (69.4% vs. 35.3%, p = 0.03) than those in the SOC group. No ropeginterferon alfa-2b-related serious adverse event was observed.

Conclusion: Our data show that ropeginterferon alfa-2b with SOC shortened the duration of SARS-CoV-2 shedding compared with SOC alone. In addition, ropeginterferon alfa-2b as an additional therapy could be beneficial by improving lung infiltration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219598PMC
http://dx.doi.org/10.1007/s40121-024-00992-5DOI Listing

Publication Analysis

Top Keywords

ropeginterferon alfa-2b
12
phase randomized
4
randomized controlled
4
controlled trial
4
trial evaluating
4
evaluating efficacy
4
efficacy safety
4
safety ropeginterferon
4
alfa-2b patients
4
patients moderate
4

Similar Publications

Article Synopsis
  • Anaemia can occur in patients with polycythemia vera (PV) due to iron deficiency from phlebotomy and the effects of treatment.
  • In recent studies involving 78 patients treated with ropeginterferon alfa-2b, there was no significant occurrence of severe anaemia, with only minor cases reported that resolved.
  • Ropeginterferon alfa-2b effectively manages PV while maintaining healthy haemoglobin levels, indicating it does not significantly impact normal red blood cell production.
View Article and Find Full Text PDF

Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates.

Pathol Res Pract

November 2024

Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy. Electronic address:

Article Synopsis
  • Hepatoid thymic carcinoma (HTC) is a rare tumor that looks similar to liver cancer, specifically found in the thymus gland, and a new case has been identified in a 40-year-old man with polycythemia vera.
  • This case involved advanced analysis of the tumor's molecular profile, noting the presence of various proteins through immunohistochemistry and significant mutations identified via whole exome sequencing.
  • The study suggests that HTC may represent an evolutionary shift in tumor characteristics, combining features of both thymic carcinoma and hepatoid tumors, indicated by the unique mutation patterns found in the cells.
View Article and Find Full Text PDF

Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.

Br J Haematol

December 2024

CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.

Article Synopsis
  • The study compared the effects of Ropeginterferon alfa-2b (Ropeg) and phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients with low-risk polycythemia vera (PV).
  • Results showed that Ropeg significantly reduced NLR, driven mainly by a drop in neutrophils, and this reduction correlated with better symptom management and lower JAK2 variant allele frequency.
  • The findings suggest that monitoring NLR could be a useful tool for guiding Ropeg treatment in early-stage low-risk PV patients, particularly when distinguishing between treatment responders and non-responders.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!